BioIVT Joins the Foundation for the National Institutes of Health Biomarkers Consortium
Westbury, NY - BioIVT announced that it has joined the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium.
The FNIH Biomarkers Consortium is a public-private biomedical research partnership. It brings together members of industry, academia, nonprofit and patient advocacy organizations, and government agencies and institutes to develop and support research to qualify promising biomarkers for diagnosing disease, predicting therapeutic response or improving clinical practice.
“We’re proud to contribute our research expertise to support the FNIH Biomarkers Consortium programs. Our research services groups will be able to assist in the development of new assays supporting diagnostic, efficacy and safety biomarker research for cancer, metabolic disorders, neuroscience, and inflammation and immunity applications,” said Amanda Woodrooffe, PhD, vice president and general manager, PHASEZERO® Research Services at BioIVT.
“We are excited to welcome BioIVT as the newest member of the FNIH Biomarkers Consortium. BioIVT’s expertise and commitment to scientific discovery will help us accelerate biomedical research to fight diseases across the world,” said Joseph P. Menetski, PhD, associate vice president for research partnerships, the FNIH.
For more information, please visitwww.bioivt.com or follow the company on Twitter @BioIVT.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
